Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung

Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung is a research organisation in Frankfurt, Germany that has taken part in 9 EU-funded projects since 2009, receiving €7.0M in EU funding and leading 4 as coordinator.

EU funding received€7.0M
EU projects9
As coordinator4
Running now2
First EU project2009
Latest project2026
CountryGermany
EU registration (PIC)997951133
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung's own share of each project, not the project's full budget.

  • Horizon 2020€5.0M · 4 projects
  • FP7 (2007 to 2013)€1.9M · 4 projects
  • Horizon Europe€150k · 1 project

Projects

9 EU-funded projects, newest first. Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung led 4 of them as coordinator. Each links to the official record.

  • INFLAME-TMECoordinator

    Inflaming the microenvironment of colorectal cancer to enable immunotherapy

    Horizon Europe · 2026–2028 · Project on CORDIS ↗

    €150ktheir share
  • PLASTICANCoordinator

    Cell Plasticity in Metastatic Colorectal Cancer

    Horizon 2020 · 2022–2026 · Project on CORDIS ↗

    €2.5Mtheir share
  • INTERCEPT-MDSPartner

    Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.

    Horizon 2020 · 2021–2024 · Project on CORDIS ↗

    €253ktheir share
  • EUbOPENPartner

    EUbOPEN: Enabling and Unlocking biology in the OPEN

    Horizon 2020 · 2020–2025 · Project on CORDIS ↗

    €738ktheir share
  • HemNichMDSCoordinator

    Functional and Molecular Analyses of the Interplay between Hematopoietic and Mesenchymal Niche Cells in Human Myelodysplastic Syndromes.

    Horizon 2020 · 2015–2022 · Project on CORDIS ↗

    €1.5Mtheir share
  • NET4CGDPartner

    Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)

    FP7 (2007 to 2013) · 2012–2018 · Project on CORDIS ↗

    €270ktheir share
  • ROSCANCoordinator

    The role of ROS/RNS during inflammation-associated and sporadic carcinogenesis

    FP7 (2007 to 2013) · 2011–2016 · Project on CORDIS ↗

    €1.0Mtheir share
  • CELL-PIDPartner

    Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency

    FP7 (2007 to 2013) · 2010–2016 · Project on CORDIS ↗

    €516ktheir share
  • PERSISTPartner

    Persisting Transgenesis

    FP7 (2007 to 2013) · 2009–2013 · Project on CORDIS ↗

    €60ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • DNA
  • chromosomes
  • colorectal cancer
  • gene therapy
  • genomes
  • immunology
  • leukemia
  • lipids
  • mutation
  • neurobiology
  • oncology
  • pharmaceutical drugs
  • proteins
  • stem cells

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime